IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
COWEN & CO (August 2008)
Sales of Key Marketed Products for years ending December 31:
Unit: $ mil lions
2007 2008(E) 2009(E) 2010(E) 2011(E) 2012(E) 2013(E)
Diovan 5,012 5,985 6,405 6,400 4,650 3,200 1,500
Exforge 103 450 750 950 1,050 900 700
Lotrel 748 375 320 200 150 100 50
Lescol 665 640 550 450 300 200 100
Galvus 8 35 40 60 80 100 120
Total Cardiovascular 7,405 8,485 9,175 9,250 7,585 6,270 4,705
Glivec 3,050 3,820 4,305 4,550 4,750 4,950 5,100
Tasigna — 65 130 200 250 300 400
Zometa 1,297 1,370 1,385 1,200 1,000 900 750
Sandostatin 1,027 1,165 1,205 1,250 1,300 1,100 600
Femara 937 1,165 1,355 1,400 1,000 500 300
Exjade 357 515 625 675 725 775 825
Total Oncology 6,951 8,420 9,425 9,785 9,715 9,655 9,435
Trileptal 692 335 300 250 200 200 150
Exelon/Patch 632 790 885 950 975 900 800
Tegretol 413 485 495 505 515 525 535
Comtan Group 420 515 575 650 700 750 350
Ritalin Group 375 415 430 445 460 475 490
Total Neuroscience 3,345 3,345 3,530 3,670 3,835 4,010 3,660
Foradil 362 415 430 400 350 300 250
Xolair 140 190 200 225 250 275 300
TOBI (to be replaced by dry
powder product in 2011) 273 295 310 180 — — —
TMB 100 (2nd generation
TOBI dry powder) — — — 150 345 360 370
Total Respiratory 959 1,090 1,190 1,305 1,470 1,935 2,395
Lucentis 397 975 1,220 1,350 1,400 1,450 1,500
Enablex 179 205 225 235 245 255 265
Zelnorm 88 15 20 10 10 10 10
Total Ophthalmics/GI/Urinary1,381 1,755 2,085 2,265 2,375 2,485 2,570
Voltaren 749 875 920 940 950 960 970
Aclasta 41 300 580 620 650 675 550
Prexige 91 45 40 40 40 40 40
Total Metabolic/Pain 1,574 1,745 2,060 2,160 2,245 2,325 2,130
Neoral/Sandimmun 944 1,030 1,005 985 955 925 900
Cubicin 14 20 40 50 75 100 125
Elidel 176 155 130 120 110 100 100
Total Immunology/
Infection 2,410 2,650 2,670 2,855 3,100 3,355 3,600
© 2009 IMS Health In cor po rated or its af fil i ates Page 113